Menu Search
Equities

Tactile Systems Technology Inc

  • Add to watchlist
  • Add to portfolio
  • Add an alert
3L3:FRA

Tactile Systems Technology Inc

Actions
  • Price (EUR)23.00
  • Today's Change0.40 / 1.77%
  • Shares traded85.00
  • 1 Year change+43.75%
  • Beta0.9751
Data delayed at least 15 minutes, as of Feb 11 2026 07:27 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Tactile Systems Technology, Inc., doing business as Tactile Medical, is a medical technology company that manufactures and distributes medical devices for the treatment of patients with chronic diseases at home. The Company's areas of therapeutic focus are vascular disease, oncology and providing airway clearance therapy for those suffering from chronic respiratory conditions. It is developing and marketing at-home therapies for people suffering from underserved, chronic conditions including lymphedema, lipedema, chronic venous insufficiency and chronic pulmonary disease. It markets Flexitouch Plus and Entre Plus systems as at-home therapies for the treatment of lymphedema and chronic venous insufficiency. It markets AffloVest as an at-home therapy intended to promote airway clearance. Its Flexitouch Plus system is a fully automated, programmable, advanced pneumatic compression device. It also offers Kylee, a free mobile application that helps patients learn about lymphedema.

  • Revenue in USD (TTM)311.51m
  • Net income in USD18.17m
  • Incorporated2006
  • Employees1.04k
  • Location
    Tactile Systems Technology Inc3701 Wayzata Blvd, Suite 300MINNEAPOLIS 55416United StatesUSA
  • Phone+1 (612) 355-5100
  • Fax+1 (612) 355-5101
  • Websitehttps://www.tactilemedical.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.